<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lunai Bioworks Inc. — News on 6ix</title>
<link>https://6ix.com/company/lunai-bioworks-inc</link>
<description>Latest news and press releases for Lunai Bioworks Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 15 Apr 2026 13:10:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lunai-bioworks-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7667151cc36e47533b176.webp</url>
<title>Lunai Bioworks Inc.</title>
<link>https://6ix.com/company/lunai-bioworks-inc</link>
</image>
<item>
<title>Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-and-geneial-sign-loi-to-build-rare-disease-patient-cohorts-for-pharma-partnerships</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-and-geneial-sign-loi-to-build-rare-disease-patient-cohorts-for-pharma-partnerships</guid>
<pubDate>Wed, 15 Apr 2026 13:10:00 GMT</pubDate>
<description>Lunai Bioworks, Inc. (NASDAQ: LNAI) ("Lunai"), an AI-driven drug discovery company, and Geneial, Inc., a precision medicine data infrastructure and patient engagement company, today announced that BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent (LOI) with Geneial to pursue a strategic collaboration in rare neurological disorders.</description>
</item>
<item>
<title>Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-secures-first-revenue-generating-defense-collaboration-through-biosymetrics-deploying-ai-platform-for-chemical-threat-assessment-additional-engagements-under-discussion</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-secures-first-revenue-generating-defense-collaboration-through-biosymetrics-deploying-ai-platform-for-chemical-threat-assessment-additional-engagements-under-discussion</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Advancing AI-enabled chemical threat detection and dual-use biodefense technologies through initial commercial deploymentSACRAMENTO, Calif., April 7, 2026</description>
</item>
<item>
<title>Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-executes-dollar20m-strategic-transaction-at-fixed-dollar150-conversion-acquiring-bbb-delivery-platform-for-cns-alzheimers-therapies-with-broad-cns-delivery-applications</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-executes-dollar20m-strategic-transaction-at-fixed-dollar150-conversion-acquiring-bbb-delivery-platform-for-cns-alzheimers-therapies-with-broad-cns-delivery-applications</guid>
<pubDate>Thu, 26 Mar 2026 12:50:00 GMT</pubDate>
<description>Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer's drug assets from the Clemann Group, SAS or its assignee.</description>
</item>
<item>
<title>Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-launches-national-chemical-defense-consortium-targeting-dollar400m-dollar12b-us-countermeasure-programs-3-year-ai-antidote-development-model</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-launches-national-chemical-defense-consortium-targeting-dollar400m-dollar12b-us-countermeasure-programs-3-year-ai-antidote-development-model</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>AI platform integrates academic and defense research to accelerate rapid antidote discovery and federal stockpiling for emerging chemical threats.SACRAMENTO,</description>
</item>
<item>
<title>Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-locks-down-core-ai-architecture-with-us-patent-enabling-precision-disease-subtyping</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-locks-down-core-ai-architecture-with-us-patent-enabling-precision-disease-subtyping</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven biotechnology company advancing precision therapeutics in central nervous system (CNS) disorders and oncology, as well as solutions for biodefense, today announced the issuance of U.S. Patent No. 12,369,861, titled "Methods, Systems, and Frameworks for Debiasing Data in Drug Discovery Predictions."</description>
</item>
<item>
<title>Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-highlights-drug-discovery-and-biodefense-ai-platform-on-cnbc</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-highlights-drug-discovery-and-biodefense-ai-platform-on-cnbc</guid>
<pubDate>Fri, 13 Feb 2026 13:31:00 GMT</pubDate>
<description>Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein shared how the company is using its proprietary AI platform to scale therapeutic discovery and strengthen biodefense preparedness.</description>
</item>
<item>
<title>Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-launches-ai-oncology-pilot-with-clinical-stage-partner-to-analyze-randomized-phase-2-metastatic-colorectal-cancer-survival-trial-data</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-launches-ai-oncology-pilot-with-clinical-stage-partner-to-analyze-randomized-phase-2-metastatic-colorectal-cancer-survival-trial-data</guid>
<pubDate>Mon, 09 Feb 2026 14:15:00 GMT</pubDate>
<description>Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced the launch of a new oncology collaboration with a clinical-stage partner to analyze data from a randomized Phase 2 metastatic colorectal cancer trial.</description>
</item>
<item>
<title>Lunai Bioworks, Inc. Issues Letter to Shareholders</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-inc-issues-letter-to-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-inc-issues-letter-to-shareholders</guid>
<pubDate>Mon, 09 Feb 2026 05:00:00 GMT</pubDate>
<description>SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders,We have completed our AI platform in the last 12 months and now it is commercial.</description>
</item>
<item>
<title>Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-launches-sentinel-an-ai-safeguard-to-block-large-language-models-from-generating-novel-chemical-weapons</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-launches-sentinel-an-ai-safeguard-to-block-large-language-models-from-generating-novel-chemical-weapons</guid>
<pubDate>Tue, 27 Jan 2026 15:36:00 GMT</pubDate>
<description>As global attention intensifies around the dual-use risks of advanced artificial intelligence in chemistry and biology, Lunai Bioworks (NASDAQ: LNAI) today announced the deployment of Sentinel™, a transformer-based AI safeguard designed to be embedded directly within large language and scientific foundation models to prevent the generation of novel chemical agents. Built on Lunai's expansive molecular AI platform and strengthened by proprietary toxicology and in-vivo phenotypic datasets, Sentine</description>
</item>
<item>
<title>Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-expands-nih-funded-ai-program-into-commercial-alcohol-use-disorder-drug-discovery</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-nasdaq-lnai-expands-nih-funded-ai-program-into-commercial-alcohol-use-disorder-drug-discovery</guid>
<pubDate>Mon, 26 Jan 2026 14:30:00 GMT</pubDate>
<description>Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution, multidimensional behavioral signatures of ethanol exposure and alcohol withdrawal. Using high-throughput vertebrate screening, the company identified distinct, reproducible neurobehavioral phenotypes that are only partially addressed by currently approved therapies, highlighting previou</description>
</item>
<item>
<title>Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-identifies-three-parkinsons-subtypes-and-prioritized-drug-targets-to-accelerate-proof-of-concept-programs-and-strategic-partnerships-in-a-dollar13b-market</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-identifies-three-parkinsons-subtypes-and-prioritized-drug-targets-to-accelerate-proof-of-concept-programs-and-strategic-partnerships-in-a-dollar13b-market</guid>
<pubDate>Tue, 09 Dec 2025 12:45:00 GMT</pubDate>
<description>Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets that may accelerate proof-of-concept programs, derisk therapeutic development, and enable strategic co-development partnerships in a growing $13 billion market.</description>
</item>
<item>
<title>Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-secures-first-licensing-loi-following-landmark-breakthrough-showing-complete-tumor-regression-in-humanized-cancer-models</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-secures-first-licensing-loi-following-landmark-breakthrough-showing-complete-tumor-regression-in-humanized-cancer-models</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>Following peer-reviewed publication and independent expert review of findings, the LOI advances Lunai's tumor-regressing immune-cell platform toward scalable</description>
</item>
<item>
<title>Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-achieves-complete-regression-of-both-primary-and-metastatic-pancreatic-tumors-in-preclinical-humanized-models-marking-a-breakthrough-in-allogeneic-cancer-immunotherapy</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-achieves-complete-regression-of-both-primary-and-metastatic-pancreatic-tumors-in-preclinical-humanized-models-marking-a-breakthrough-in-allogeneic-cancer-immunotherapy</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines". LOS ANGELES, Nov. 5, 2025</description>
</item>
<item>
<title>Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-harnesses-ai-and-zebrafish-data-to-advance-early-detection-of-neurotoxic-compounds</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-harnesses-ai-and-zebrafish-data-to-advance-early-detection-of-neurotoxic-compounds</guid>
<pubDate>Thu, 30 Oct 2025 13:32:00 GMT</pubDate>
<description>NEW YORK, NY / ACCESS Newswire / October 30, 2025 / In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (NASDAQ:LNAI) today announced promising early results from its ...</description>
</item>
<item>
<title>Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-regains-compliance-with-nasdaq-minimum-bid-price-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-regains-compliance-with-nasdaq-minimum-bid-price-requirement</guid>
<pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
<description>LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 16, 2025 / Lunai Bioworks, Inc. (Nasdaq:LNAI), today announced that it has regained compliance with</description>
</item>
<item>
<title>Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-launches-ai-powered-alzheimers-disease-program-expanding-neurodegenerative-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-launches-ai-powered-alzheimers-disease-program-expanding-neurodegenerative-pipeline</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 6, 2025 / Lunai Bioworks (Nasdaq:LNAI) today announced a major advance in Alzheimer's research: its AI</description>
</item>
<item>
<title>Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-unveils-new-corporate-identity-streamlined-capital-structure-and-strategic-focus-on-ai-powered-therapeutics-and-biodefense</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-unveils-new-corporate-identity-streamlined-capital-structure-and-strategic-focus-on-ai-powered-therapeutics-and-biodefense</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Lunai Bioworks Inc. (Nasdaq:LNAI), a pioneer in AI-powered drug discovery and biodefense,</description>
</item>
<item>
<title>Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-advances-biomarker-discovery-preclinical-program-in-parkinsons-disease-positioning-for-strategic-pharma-partnerships</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-advances-biomarker-discovery-preclinical-program-in-parkinsons-disease-positioning-for-strategic-pharma-partnerships</guid>
<pubDate>Thu, 25 Sep 2025 04:00:00 GMT</pubDate>
<description>NEW YORK CITY, NEW YORK / ACCESS Newswire / September 25, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery company and parent of wholly</description>
</item>
<item>
<title>Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split</title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-inc-to-effect-101-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-inc-to-effect-101-reverse-stock-split</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price LOS ANGELES, CA / ACCESS Newswire / September 24, 2025 / Lunai Bioworks, Inc.</description>
</item>
<item>
<title>Lunai Bioworks Strengthens European Strategy Through Restructuring </title>
<link>https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-strengthens-european-strategy-through-restructuring</link>
<guid isPermaLink="true">https://6ix.com/company/lunai-bioworks-inc/news/lunai-bioworks-strengthens-european-strategy-through-restructuring</guid>
<pubDate>Mon, 08 Sep 2025 04:00:00 GMT</pubDate>
<description>Company remains committed to Europe with a streamlined, growth-focused approach. LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 8, 2025 / Lunai</description>
</item>
</channel>
</rss>